Memantine (Namenda) for moderate to severe Alzheimer's disease

被引：0
|
作者：
Ables, AZ [1 ]
机构：
[1] Spartanburg Family Med Residency Program, Spartanburg, SC USA
来源：
AMERICAN FAMILY PHYSICIAN | 2004年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Synopsis: Memantine (Namenda) is an N-methyl-d-aspartate'(NMDA) receptor blocker indicated for the treatment of moderate to severe Alzheimer's disease (AD). The NMDA receptor is activated by glutamate, the primary excitatory neurotransmitter in the brain. Overstimulation by glutamate may result in neuronal damage and has been implicated in neurodegenerative disorders such as AD. Memantine is the first pharmacologic agent approved by the US. Food and Drug Administration for the treatment of moderate to severe AD.
引用
收藏
页码：1491 / 1492
页数：2
相关论文
共 50 条
  • [1] Memantine in moderate to severe Alzheimer’s disease
    Andrew Kertesz
    Current Neurology and Neuroscience Reports, 2003, 3 (6) : 485 - 486
  • [2] Efficacy of memantine in moderate to severe Alzheimer's disease
    Wilkinson, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 318 - 318
  • [3] Memantine in moderate-to-severe Alzheimer's disease
    Reisberg, B
    Doody, R
    Stoffler, A
    Schmitt, F
    Ferris, S
    Mobius, HJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14): : 1333 - 1341
  • [4] Memantine in moderate-to-severe Alzheimer's disease
    Bleich, S
    Wiltfang, J
    Kornhuber, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06): : 609 - 610
  • [5] Spotlight on Memantine in Moderate to Severe Alzheimer's Disease
    McKeage, Kate
    DRUGS & AGING, 2010, 27 (02) : 177 - 179
  • [6] Memantine therapy in patients with moderate to severe Alzheimer's disease
    Ochudlo, S
    Targosz, M
    Liberska, A
    Opala, G
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 235 - 235
  • [7] Management of moderate to severe Alzheimer's disease: Focus on memantine
    Dominguez, Evangelyn
    Chin, Ting-Yu
    Chen, Chih-Ping
    Wu, Tzong-Yuan
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2011, 50 (04): : 415 - 423
  • [8] Overview of memantine data in moderate to severe Alzheimer's disease
    Wilkinson, David
    NEUROBIOLOGY OF AGING, 2008, 29 : S25 - S26
  • [9] Responders to memantine treatment in moderate to severe Alzheimer's disease
    Stöffler, A
    Ferris, SH
    Wirth, Y
    Reisberg, B
    NEUROBIOLOGY OF AGING, 2004, 25 : S212 - S212
  • [10] Memantine in moderate-to-severe Alzheimer's disease - Reply
    Reisberg, B
    Doody, R
    Mobius, HJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06): : 610 - 610
12345